What is Leerink Partnrs’ Forecast for TVTX FY2026 Earnings?

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Equities research analysts at Leerink Partnrs lifted their FY2026 earnings per share (EPS) estimates for shares of Travere Therapeutics in a report issued on Tuesday, February 11th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings per share of $0.63 for the year, up from their prior forecast of $0.52. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.90) per share.

Several other research analysts also recently issued reports on the stock. Wells Fargo & Company upgraded shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $9.00 to $27.00 in a research note on Monday, October 21st. Barclays upped their price objective on Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. Piper Sandler lifted their target price on Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a report on Thursday, November 14th. HC Wainwright boosted their price target on Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, January 15th. Finally, Evercore ISI increased their price objective on Travere Therapeutics from $33.00 to $45.00 and gave the company an “outperform” rating in a research report on Wednesday. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $27.77.

Travere Therapeutics Price Performance

Shares of NASDAQ TVTX opened at $23.72 on Thursday. The company has a 50 day simple moving average of $19.14 and a two-hundred day simple moving average of $16.01. Travere Therapeutics has a fifty-two week low of $5.12 and a fifty-two week high of $25.29. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of -5.21 and a beta of 0.72. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Jennison Associates LLC purchased a new stake in shares of Travere Therapeutics in the fourth quarter valued at about $14,222,000. Renaissance Technologies LLC boosted its holdings in Travere Therapeutics by 28.5% in the 4th quarter. Renaissance Technologies LLC now owns 2,409,514 shares of the company’s stock valued at $41,974,000 after purchasing an additional 534,500 shares during the last quarter. Invesco Ltd. grew its stake in shares of Travere Therapeutics by 135.2% in the 4th quarter. Invesco Ltd. now owns 858,942 shares of the company’s stock valued at $14,963,000 after buying an additional 493,736 shares during the period. abrdn plc acquired a new stake in shares of Travere Therapeutics during the 4th quarter worth approximately $6,829,000. Finally, Prudential Financial Inc. raised its position in shares of Travere Therapeutics by 60.5% during the 4th quarter. Prudential Financial Inc. now owns 969,141 shares of the company’s stock valued at $16,882,000 after buying an additional 365,200 shares during the period.

Insider Buying and Selling

In other news, CEO Eric M. Dube sold 11,375 shares of the firm’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $24.04, for a total transaction of $273,455.00. Following the sale, the chief executive officer now owns 419,173 shares of the company’s stock, valued at $10,076,918.92. This trade represents a 2.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Sandra Calvin sold 54,244 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total transaction of $1,356,100.00. Following the sale, the chief accounting officer now directly owns 54,410 shares in the company, valued at $1,360,250. This trade represents a 49.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 218,425 shares of company stock worth $4,674,259 in the last three months. Corporate insiders own 3.75% of the company’s stock.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.